Structure Therapeutics Inc. (GPCR)
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Structure Therapeutics Inc.
NASDAQ:GPCRHealthcare · Biotechnology
-0.32%$21.87
AH$22.01+0.64%vs close
Mkt Cap$1.56B
Float28.65M
O/S71.31M
Vol
$ Vol
RVOL
Inst Own94.7%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$141.2M
Total Assets$1.58B
Free Cash Flow-$225.81M
Debt & Equity
Debt 0%
Equity 100%
Total Debt$6.49M
Total Equity$1.52B
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in GPCR's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$1.58B
Liabilities$67.54M
Accounts Receivable$0
Accounts Payable$13.86M
Inventory$0
PP&E (Net)$12.9M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - |
| Cost of Revenue | $3.9M | $0 | $0 | $0 | $0 | $20K |
| Gross Profit | -$3.9M | $0 | $0 | $0 | $0 | -$20K |
| Gross Margin | - | - | - | - | - | - |
| Research and Development | $225.25M | $108.81M | $70.1M | $36.19M | $29.11M | $12.39M |
| Selling, General, and Administrative | $61.55M | $49.41M | $32.67M | $16.37M | $8.59M | $3.53M |
| Other | -$3.14M | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $283.67M | $158.23M | $102.78M | $52.56M | $37.7M | $15.91M |
| Operating Income (EBIT) | -$287.57M | -$158.23M | -$102.78M | -$52.56M | -$37.7M | -$15.93M |
| Operating Margin | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $13.39M | $0 | $122K | $0 |
| Interest Income | $35.97M | $36.03M | $13.38M | $1.26M | $122 | $168K |
| Other Income (Expense) | $146.51M | $36.01M | $13.39M | $1.26M | -$122K | $168K |
| Income Before Tax (EBT) | -$140.69M | -$122.22M | -$89.38M | -$51.3M | -$37.82M | -$15.77M |
| Income Tax Expense | $515K | $310K | $236K | $17K | $231K | $138K |
| Net Income | -$141.2M | -$122.53M | -$89.62M | -$51.32M | -$40.01M | -$15.9M |
| Net Income Margin | - | - | - | - | - | - |
| Supplementary Data | ||||||
| EPS | -2.40 | -2.34 | -2.43 | -1.44 | -1.20 | -0.45 |
| Diluted EPS | -2.40 | -2.34 | -2.43 | -1.44 | -1.20 | -0.45 |
| Weighted Average OS | 59.20M | 52.64M | 36.73M | 36.59M | 36.59M | 36.59M |
| EBITDA | -$139.35M | -$121.22M | -$75.7M | -$51.03M | -$37.62M | -$15.75M |
| EBITDA Margin | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $799.62M | $169.51M | $129.79M | $26.09M | $105.31M | $16.35M |
| Short-Term Investments | $646.57M | $714.01M | $337.53M | $64.75M | $2M | $21.09M |
| Cash and Short-Term Investments | $1.45B | $883.52M | $467.32M | $90.84M | $107.31M | $37.45M |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $124.11M | $7.69M | $6.29M | $2.25M | $0 | $0 |
| Total Current Assets | $1.57B | $891.21M | $473.61M | $93.09M | $109.25M | $38.42M |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $12.9M | $7.01M | $8.36M | $1.29M | $1.79M | $277K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $717K | $5.11M | $45K | $3.46M | $111K | $8K |
| Total Long-Term Assets | $13.62M | $12.12M | $8.41M | $4.76M | $1.91M | $285K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $1.58B | $903.33M | $482.02M | $97.84M | $111.16M | $38.7M |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $13.86M | $8.02M | $4.74M | $6.01M | $3.48M | $1.53M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $356K | $174K | $231K | $138K |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $12.43M | $7.29M | $4.33M | $3.54M | $1.94M | $819K |
| Total Current Liabilities | $63.28M | $36.02M | $24.74M | $13.01M | $8.66M | $3.04M |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $3.61M | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $647K | $302K | $298K | $199.97M | $166.96M | $58M |
| Total Long-Term Liabilities | $4.26M | $2.47M | $4.31M | $199.97M | $167.23M | $58.13M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $67.54M | $38.49M | $29.05M | $212.99M | $175.89M | $61.17M |
| Stockholders' Equity | ||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $21K | $17K | $14K | $1K | $1K | $1K |
| Retained Earnings | -$470.3M | -$329.1M | -$206.57M | -$116.95M | -$64.74M | -$22.95M |
| Comprehensive Income & Other | $1.05M | $914K | $521K | -$110K | $0 | -$1K |
| Other Stockholders' Equity | $1.99B | $1.19B | $659.52M | $1.81M | $0 | $476K |
| Total Equity | $1.52B | $864.84M | $452.97M | -$115.14M | -$64.73M | -$22.47M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $1.58B | $903.33M | $482.02M | $97.84M | $111.16M | $38.7M |
| Supplementary Data | ||||||
| Total Debt | $6.49M | $3.86M | $5.45M | $260K | $621K | $280K |
| Net Debt | -$793.14M | -$165.65M | -$124.34M | -$25.83M | -$104.68M | -$16.07M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Operating Activities | ||||||
| Net Income | -$141.2M | -$122.53M | -$89.62M | -$51.32M | -$38.05M | -$15.88M |
| Depreciation & Amortization | $1.33M | $992K | $295K | $277K | $72K | $20K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $28.99M | $18.79M | $8.19M | $2.51M | $1.49M | $570K |
| Changes in Working Capital: | ||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $4.76M | $3.31M | -$859K | $2.15M | $1.9M | $1.02M |
| Other Working Capital | -$93.05M | -$343K | $7.83M | $815K | $2.17M | -$74K |
| Total Working Capital Change | -$88.27M | $2.96M | $6.97M | $2.97M | $4.06M | $946K |
| Other Non-Cash Items | -$23.05M | -$16.86M | -$5.32M | -$558K | $268K | $57K |
| Net Cash from Operating | -$222.2M | -$116.64M | -$79.49M | -$46.12M | -$32.16M | -$14.28M |
| Investing Activities | ||||||
| Capital Expenditures | -$3.61M | -$1.29M | -$2.17M | -$155K | -$1.21M | -$19K |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$547.38M | -$702.52M | -$416.99M | -$123.45M | -$4.21M | -$21.13M |
| Sales of Investments | $630.54M | $344.9M | $151.05M | $61.5M | $23.28M | $0 |
| Other Investing Activities | $10.25M | $0 | -$231K | $0 | $0 | $0 |
| Net Cash from Investing | $89.8M | -$358.91M | -$268.34M | -$62.11M | $17.86M | -$21.15M |
| Financing Activities | ||||||
| Debt Repaid | - | - | - | - | - | - |
| Common Stock Issuance | $767.18M | $514.57M | $472.3M | $0 | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$4.66M | $690K | -$20.77M | -$2.49M | -$104K | $0 |
| Net Cash from Financing | $762.52M | $515.26M | $451.53M | $29.01M | $103.25M | $25.84M |
| Forex Effect | -$1.66M | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $630.12M | $39.72M | $103.7M | -$79.21M | $88.95M | -$9.59M |
| Supplementary Data | ||||||
| Operating Cash Flow | -$222.2M | -$116.64M | -$79.49M | -$46.12M | -$32.16M | -$14.28M |
| Capital Expenditure | -$3.61M | -$1.29M | -$2.17M | -$155K | -$1.21M | -$19K |
| Free Cash Flow | -$225.81M | -$117.93M | -$81.66M | -$46.27M | -$33.37M | -$14.3M |
| Cash at Beginning | $169.51M | $129.79M | $26.09M | $105.31M | $16.35M | $25.95M |
| Cash at End | $799.63M | $169.51M | $129.79M | $26.09M | $105.31M | $16.35M |